Abstract
Introduction:
Many people expressed concern over coronavirus vaccinations’ reliability and side effects. This research aimed to assess university students’ perceptions and experiences regarding the side effects of the COVID-19 vaccines in Bangladesh.
Method:
We conducted an online cross-sectional survey to collect responses from university students vaccinated with any vaccines administered in Bangladesh between November 2021 to April 2022. Bangladeshi university students over the age of 18 and having an internet connection was included in the study. A binary logistic regression analysis along with Pearson’s Chi-square test were used to identify COVID-19 vaccine-related side effects predictors after receiving the first dose.
Results:
A total of 1,176 participants responded voluntarily to the online study, and most were vaccinated. More than half of the participants received the Sinopharm vaccine (56.5%), while others received Covishield (8.9%), Moderna (7.3%), and Pfizer (5.8%) vaccine. Around 32% of the participants reported side effects after receiving the first dose of the vaccine, including pain and edema (78.4%), body temperature (20.3%), and headache (14.5%), while a few experienced allergy, anxiety, and uneasy feelings. About 17% of the participants reported experiencing side effects after the second dose of the vaccine, including pain and edema (7.5%), body temperature (8.8%), and headache (7.3%). Most side effects were significantly associated with the Moderna vaccine (p < 0.001). Female students and those previously infected with COVID-19 were significantly associated with the side effects after taking the first dose of the vaccine.
Conclusion:
We found that side effects are mild and did not pose a significant challenge to Bangladesh’s effort in managing and reducing the risk associated with the COVID-19 pandemic.
1 Introduction
The dreadful spread of SARS-CoV-2 virus with its several arbitrarily mutated variants has been a severe global health concern due to the horrendous catastrophic effects on every sector of life across the world (1, 2). Following the declaration of the COVID-19 outbreak as a pandemic on March 11, 2020 by WHO, an ample amount of confirmed cases of the infection and deaths are being reported throughout the world till now (3). As of March 03, 2024, the number of reported confirmed cases is over 77,48,34,251, including 70,37,007 deaths (4). The abundance of the infection is higher in Europe and the Americas than in the Western Pacific and South-East Asia, Eastern Mediterranean, and Africa (4). In Bangladesh, the very first three cases of the SARS CoV-2 infection were confirmed and reported on March 08 2020, by the ‘Institute of Epidemiology, Disease Control and Research (IEDCR)’ (5, 6). Since then, both the rates of infection and death have been increasing across the country. As of March 03 2024, the nationwide numerical value of COVID-19 confirmed cases is 20,48,588, including a total of 29,491 deaths (4).
As a curative measure, several existing allopathic drugs, herbal medicines, and bioactive phytoconstituents found to be somewhat functional against coronavirus disease (2, 7); but yet to achieve herd immunity against COVID-19 vaccines are considered as promising preventive candidates. Because vaccines have been found to be effective against viral infections earlier (8). Therefore, on an emergency basis, to eliminate the spread and catastrophic effects of the novel strains of SARS CoV-2 virus around the world, several vaccines have been licensed worldwide with a short period of development stage (9); including Pfizer (96% efficacy rate), Moderna (94.10% efficacy rate), AstraZeneca-Oxford (70% efficacy rate) and Russian Sputnik V (92% efficacy rate) (10). As of November 26 2023, a total of 13.59 billion doses of different vaccines have been administered worldwide (4). While the Bangladeshi government commenced its nationwide mass vaccination program on February 07, 2021, prioritizing the frontline personnel, doctors, nurses, and older adult people on an initial basis, which is currently applicable for anybody over 18 years old with National Identity Card (10). Notably, the government also brought a massive number of students under vaccination coverage to resume the regular educational scheme after an extensive lockdown phase, which was imposed in the earlier days of the pandemic (10). As of November 26, 2023, in Bangladesh, a total of 15,15,04,394 vaccine doses have been administered nationwide (4); which include five different vaccines, namely, AstraZeneca (Covishield), Pfizer-BioNTech, Sinopharm, Moderna and Sinovac (Coronavac) (4).
Bangladesh began an extensive mass vaccination campaign for anyone above 18 with a national identity to deliver immunizations to university students (11). Despite significant advances in vaccination rollouts, vaccine hesitancy remains a key concern and a barrier to mass immunization success (12, 13). Vaccine reluctance and acceptance are multifaceted, and vaccine responses might differ depending on context, time, vaccine type, and geographical location (14). Despite the availability of vaccination services, vaccine hesitancy is defined as a delay in accepting or avoiding immunization (15). Hence, the precise causes of vaccination apprehension are unknown (16). However, the rate of acceptance or reluctance to take COVID-19 vaccination among Bangladeshis is different from that of other countries due to a lack of public awareness about the efficacy of these novel vaccines, the availability of several different manufacturer’s vaccines, the spread of controversial news in media, mistrust, misconception and cultural, religious, gender or other contemporary socioeconomic factors (17, 18).
For the implementation and estimation of the effectiveness of a nationwide mass vaccination campaign, we need to analyze and study the knowledge, thoughts, attitudes, responses, and opinions of the country’s common people about vaccination (19). Though several considerable survey researches regarding progression and perceptions of pre-and post-vaccination programs at times have been conducted on diversified common Bangladeshi people (11, 17, 20), surveys including the resident and non-resident university students can hardly be found. In addition, the public health sector demands more permutated survey studies in order to ensure broader community uptake of vaccines.
Therefore, this study’s core and primary objective was to explore the behavioral measurements and perceptions regarding COVID-19 vaccination of Bangladeshi undergraduate and post-graduate students of different ages, genders, religions, regions, and lifestyles from different universities across the country. The secondary objective of the study was to estimate the possible side effects of vaccination among the participants along with its relationship with the participant’s gender. Hopefully, the findings of this study will help the country’s respective legislators correlate the public health sector with the education sector.
2 Methods
2.1 Study design and participants
After Bangladesh launched the COVID-19 vaccination programs, a cross-sectional online survey of university students was conducted from November 2021 to April 2022 in order to portray the actual scenario regarding the perception and experience of the COVID-19 vaccination. This online survey was conducted irrespective of location and type (general or technical) of universities across Bangladesh, where the participants were selected using convenience sampling based on some specifications: (i) s/he must have access to the internet; (ii) s/he must be enrolled in the regular programs (undergraduate and postgraduate programs) universities of Bangladesh; (iii) s/he must be over 18 years of age; and (iv) s/he must be eligible for the vaccination program initiated by the universities. Considering the aforementioned criteria, university students were approached through social media (e.g., Facebook, Messenger, Instagram, WhatsApp, LinkedIn), and a total of 1,176 valid responses were retained in this study.
2.2 E-questionnaire
The e-questionnaire used in this online-based cross-sectional study was developed based on the existing literature (9, 11, 21, 22), and the e-questionnaire was in English as the medium of instruction in tertiary education in Bangladesh is English. The e-questionnaire has five modules; Section I extracted socio-demographic information, including age, religion, sex, residence, marital status, living arrangement, and household composition; Section II focused on the information of their respective educational institutions, such as the name of the university, level of education, and department/discipline; Section III highlighted the health status of the participants, including presence or absence of chronic diseases; while Section IV and section V contained questions regarding vaccination and their experience and opinion regarding the COVID-19 vaccine, respectively. The survey inquired about participants’ experiences and opinions regarding COVID-19 vaccination, including level of side effects (if any), physical or mental illness and types of such illness, medication usage to reduce the side effects, concerns about receiving the second dose, post-vaccination symptoms, hospitalization, recovery duration, and post-recovery difficulties.
2.3 Consent and ethical considerations
The institutional ethical clearance committee has approved this study (Protocol Number – KUECC-2021/11/32). In this study, the participants participated voluntarily after filling out a written informed consent form that assured their anonymity and the confidentiality of information. Moreover, the participants were free to decline the online survey without providing any prior explanation.
2.4 Statistical analysis
Data were analyzed using IBM SPSS Statistics (version 26.0) and Microsoft Excel 2019. After closing the online survey, the data were cleaned, sorted, edited – where necessary, and coded in Microsoft Excel. Later, the Excel file was imported into SPSS. First-order analysis, i.e., descriptive statistics and Pearson’s Chi-square (χ2), were used to describe the participants’ basic characteristics and identify their association with COVID-19 vaccine-related side effects. A binary logistic regression analysis was conducted to identify COVID-19 vaccine-related side effects predictors after receiving the first dose. The results included the odds ratio (OR) at a 95% confidence interval (CI). A p-value of 0.05 or less was used to establish what constitutes a statistically significant difference or association between the test populations.
3 Patient and public involvement
No patients were involved in this study.
4 Results
Among the participants, the majority fall in the age group of 22 to 24 years, which is 52%. Others fall into the age group of 18 to 21 years (36.4%), and rest of the participants are older than 25 years old (11.6%). 59% of respondents are male, while the remaining 41% are female. Islam is the most widely followed religion (86.9%), and 13.1% of respondents are from other religions. People partaking in the survey are mostly living with their families (55.9%), and 44.1% of the participants have made their living arrangements on their own. Most of the participants (87.7%) are either undergrads or graduates, and the rest have postgraduates’ degrees or other qualifications. Table 1 presents additional significant demographic characteristics of respondents. Fifty-six percent of the respondents have a good history of health, 35.2% have suffered from allergy diseases, and very few people had asthma, diabetes, heart disease, hypertension, or tuberculosis. 71.6% of the contributors did not test for COVID-19 as there were no symptoms, whereas 13.5% of the respondents did not test but had all the symptoms. 9.6% and 5.3% of people tested negative and positive for COVID-19, respectively. As most of the people did not test for COVID-19, the recovery period is not applicable to them, but 5.4% of participants have taken 1 to 3 days to fully recover, and 2% of people have taken more than 3 days to recover. 84.4% of the respondents have taken at least one dose of the vaccine; 226 completed the first dose, and 756 took both doses. Most of the participants who have taken the vaccine have taken Sinopharm, which is 56.5%. 63.4% of the total participants did not maintain at least 1.5 meters of social distancing, whereas the rest of the 36.6% maintained it. The majority of the respondents (85.5%) have continued to wear a face mask or shield. 73.5% of the participants have not continued washing or sanitizing their hands. 63.4% of the respondents covered their noses and mouths while coughing and sneezing. It is observed that 68.1% of the respondents did not experience any physical or mental illness after taking the first dose of the vaccine, and the remainder have faced either one or more illnesses.
Table 1
| Variable | Level | N | % |
|---|---|---|---|
| Socio-demographic information | |||
| Age (in years) | |||
| 18–21 | 428 | 36.4 | |
| 22–24 | 611 | 52.0 | |
| 25< | 137 | 11.6 | |
| Sex | |||
| Male | 694 | 59.0 | |
| Female | 482 | 41.0 | |
| Religion | |||
| Islam | 1,022 | 86.9 | |
| Others | 154 | 13.1 | |
| Living arrangement | |||
| Alone | 519 | 44.1 | |
| With family | 657 | 55.9 | |
| Education | |||
| Undergraduate | 1,031 | 87.7 | |
| Postgraduates and others | 145 | 12.3 | |
| Division | |||
| Khulna | 276 | 23.5 | |
| Dhaka | 318 | 27.0 | |
| Rangpur | 193 | 16.4 | |
| Chittagong | 165 | 14.0 | |
| Barishal | 35 | 3.0 | |
| Mymensingh | 59 | 5.0 | |
| Rajshahi | 120 | 10.2 | |
| Sylhet | 10 | 0.9 | |
| Residence | |||
| Rural | 274 | 23.3 | |
| Sub-urban | 239 | 20.3 | |
| Urban | 663 | 56.4 | |
| Marital status | |||
| Unmarried | 1,079 | 91.8 | |
| Married | 96 | 8.2 | |
| Divorced | 1 | 0.1 | |
| Health status during COVID-19 | |||
| Health status | |||
| Poor | 134 | 11.4 | |
| Good | 658 | 56.0 | |
| Excellent | 384 | 32.7 | |
| Diseases | |||
| Allergy diseases | 414 | 35.2 | |
| Asthma diseases | 69 | 5.9 | |
| Diabetes diseases | 6 | 0.5 | |
| Heart diseases | 6 | 0.5 | |
| Hypertension diseases | 41 | 3.5 | |
| Tuberculosis diseases | 1 | 0.1 | |
| COVID-19 infection | |||
| Tested negative | 113 | 9.6 | |
| Tested positive | 62 | 5.3 | |
| I did not test, but I had all the symptoms | 159 | 13.5 | |
| I did not test, because I did not have any symptoms | 842 | 71.6 | |
| Recovery from infection | |||
| Not applicable | 1,088 | 92.5 | |
| 1–3 days | 64 | 5.4 | |
| Above 3 days | 24 | 2.0 | |
| Preventive measures among people in the last 7 days | |||
| Never | 514 | 43.7 | |
| Once | 187 | 15.9 | |
| Always | 475 | 40.4 | |
| COVID-19 vaccination | |||
| Vaccination status | |||
| Yes | 992 | 84.4 | |
| No | 184 | 15.6 | |
| First dose taken | |||
| Yes | 226 | 19.2 | |
| No | 950 | 80.8 | |
| Second dose taken | |||
| Yes | 756 | 64.3 | |
| No | 420 | 35.7 | |
| Vaccine | |||
| Moderna | 86 | 7.3 | |
| Covisheild | 105 | 8.9 | |
| Sinopharm | 665 | 56.5 | |
| Pfizer–BioNTech | 68 | 5.8 | |
| Sinovac (Coronavac) | 21 | 1.8 | |
| Sputnik V | 2 | 0.2 | |
| Janssen (Johnson & Johnson) | 1 | 0.1 | |
| Not Applicable | 228 | 19.4 | |
| Social distancing in public spaces | |||
| Yes | 430 | 36.6 | |
| No | 746 | 63.4 | |
| Wearing face mask/shield | |||
| Yes | 1,005 | 85.5 | |
| No | 171 | 14.5 | |
| Washing or sanitizing hands | |||
| Yes | 312 | 26.5 | |
| No | 864 | 73.5 | |
| Covering mouth and nose when coughing and sneezing | |||
| Yes | 746 | 63.4 | |
| No | 430 | 36.6 | |
| Physical or mental illness after taking the first dose of the vaccine | |||
| Yes | 375 | 31.9 | |
| No | 801 | 68.1 | |
| Physical or mental illness after 1st dose | |||
| Pain and edema | |||
| Yes | 254 | 21.6 | |
| No | 922 | 78.4 | |
| Headache | |||
| Yes | 170 | 14.5 | |
| No | 1,006 | 85.5 | |
| Increased body temperature | |||
| Yes | 239 | 20.3 | |
| No | 937 | 79.7 | |
| Loss of appetite | |||
| Yes | 19 | 1.6 | |
| No | 1,157 | 98.4 | |
| Allergy | |||
| Yes | 25 | 2.1 | |
| No | 1,151 | 97.9 | |
| Rash/Itching | |||
| Yes | 15 | 1.3 | |
| No | 1,161 | 98.7 | |
| Imbalance/lethargic | |||
| Yes | 9 | 0.8 | |
| No | 1,167 | 99.2 | |
| High blood pressure | |||
| Yes | 8 | 0.7 | |
| No | 1,168 | 99.3 | |
| Low blood pressure | |||
| Yes | 15 | 1.3 | |
| No | 1,161 | 98.7 | |
| Anxiety | |||
| Yes | 27 | 2.3 | |
| No | 1,149 | 97.7 | |
| Uneasy feeling/tension | |||
| Yes | 62 | 5.3 | |
| No | 1,114 | 94.7 | |
| Pain and edema | |||
| Yes | 254 | 21.6 | |
| No | 922 | 78.4 | |
| Medicine taken after the side effects of the first dose | |||
| Yes | 250 | 21.3 | |
| No | 926 | 78.7 | |
| Medicine after first dose | |||
| Painkiller | |||
| Yes | 92 | 7.8 | |
| No | 1,084 | 92.2 | |
| Sedative | |||
| Yes | 5 | 0.4 | |
| No | 1,171 | 99.6 | |
| Anti-allergic medicine | |||
| Yes | 13 | 1.1 | |
| No | 1,163 | 98.9 | |
| Fever medicine | |||
| Yes | 183 | 15.6 | |
| No | 993 | 84.4 | |
| Medications for abnormal high blood pressure | |||
| Yes | 3 | 0.3 | |
| No | 1,173 | 99.7 | |
| Physical or mental illness after second dose | |||
| Physical or mental illness after taking the second dose | |||
| Yes | 194 | 16.5 | |
| No | 631 | 53.7 | |
| Pain and edema | |||
| Yes | 88 | 7.5 | |
| No | 1,088 | 92.5 | |
| Headache | |||
| Yes | 86 | 7.3 | |
| No | 1,090 | 92.7 | |
| Increased body temperature | |||
| Yes | 104 | 8.8 | |
| No | 1,072 | 91.2 | |
| Loss of appetite | |||
| Yes | 1,157 | 98.4 | |
| No | 19 | 1.6 | |
| Allergy | |||
| Yes | 20 | 1.7 | |
| No | 1,156 | 98.3 | |
| Anxiety | |||
| Yes | 8 | 0.7 | |
| No | 1,168 | 99.3 | |
| Imbalance/lethargic | |||
| Yes | 2 | 0.2 | |
| No | 1,174 | 99.8 | |
| Rash/Itching | |||
| Yes | 9 | 0.8 | |
| No | 1,167 | 99.2 | |
| Low BP | |||
| Yes | 4 | 0.3 | |
| No | 1,172 | 99.7 | |
| Medicine second dose | |||
| Fever medicine | |||
| Yes | 95 | 8.1 | |
| No | 1,081 | 91.9 | |
| Painkiller | |||
| Yes | 42 | 3.6 | |
| No | 1,134 | 96.4 | |
| Anti-allergic medicine | |||
| Yes | 4 | 0.3 | |
| No | 1,172 | 99.7 | |
| Admitted it the hospital or ICU after taking the vaccine | |||
| Yes | 13 | 1.1 | |
| No | 1,163 | 98.9 | |
Baseline characteristics of different selected variables.
After the first dose of the vaccine, there was no experience of pain and edema (78.4%), headache (85.5%), or increased body temperature (79.7%). There was no loss of appetite (98.4%) or allergy (97.9%). Few people have experienced allergy symptoms after taking the first dose.
Among other medical statuses, there was no experience of rash or itching on the skin (98.7%), no imbalance or lethargic behavior (99.2%), no high blood pressure (99.3%), and no low blood pressure problem (98.7%). Among the mental conditions, 97.7% did not feel any anxiety, and 94.7% had no uneasy feelings or tension.
As a result of all these medical conditions, 78.7% of the participants did not take any medicine for the side effects after taking the first dose of the vaccine, and 21.3% of the respondents have taken either one or more medicines to mitigate the side effects. Most (92.2%) of the participants have not taken any painkiller, and almost everyone (99.6%) has not taken any sedative after taking the first dose of the vaccine. No use of anti-allergic medicine (98.9%), fever medicine (84.4%), or high blood pressure medicine (99.7%) was seen among the respondents.
16.5% of the participants reported at least one kind of mental or physical illness, but the majority reported no such problems (53.7%) after taking the second dose of the vaccine. Among medical conditions after taking the second dose of the vaccine, no pain and edema (92.5%), no headache (92.7%), no rise in body temperature (91.2%), no loss of appetite (99.2%), and no anxiety (99.3%) were seen among the participants. Almost everyone who took the second medicine reported no rash, itching (99.2%), or abnormally low blood pressure (99.7%). As a result, the no fever medicine (91.9%) and no painkiller and anti-allergic medicine (98.9%) intake was very high after the second dose. The vast majority (98.9%) reported no admission to the hospital or I.C.U. after taking any dose of the vaccine after being infected with COVID-19.
Table 2 shows a significant difference in side effects between male and female participants with a previous history of COVID-19 infection after each dose of the vaccine. Analysis shows that female participants experience side effects more than male participants in both the first and second doses. There was a significant difference in the number of patients reporting pain and edema (18.6% male and 25.9% female) after receiving the first and second doses of the vaccine (males 5.2% and females 10.8%). Moreover, the result shows a significant (p = 0.016) difference in the headache for gender (males 12.4% and females 17.4%) in the first dose but no significant (p = 0.279) difference after the second dose. There is a significant association between gender and increased body temperature (p = 0.008 for the first dose and p = 0.005 for the second dose) after each dose of the vaccine. In both cases, increased body temperature is reported mostly by female participants. It is also seen that there is a significant (p = 0.003) symptom of appetite loss from males (0.7%) to females (2.9%) in the first dose, although there is no significant (p = 0.372) difference between males (0.6%) and females (1.0%) after the second dose.
Table 2
| Experience and symptoms | After 1st dose of COVID-19 vaccine frequency (%) | After 2nd dose of COVID-19 vaccine frequency (%) | ||||
|---|---|---|---|---|---|---|
| Male N = 684 | Female N = 482 | p-value | Female N = 482 | Male N = 684 | p-value | |
| Experience of side effects after COVID-19 vaccination | ||||||
| No | 502 (72.3) | 299 (62.0) | <0.001 | 400 (57.6) | 231 (47.9) | <0.001 |
| Yes | 192 (27.7) | 183 (38.0) | 91 (13.1) | 103 (21.4) | ||
| Symptoms | ||||||
| Pain and Edema | 129 (18.6) | 125 (25.9) | 0.003 | 36 (5.2) | 52 (10.8) | <0.001 |
| Headache | 86 (12.4) | 84 (17.4) | 0.016 | 46 (6.6) | 40 (8.3) | 0.279 |
| Increased body temperature | 123 (17.7) | 116 (24.1) | 0.008 | 48 (6.9) | 56 (11.6) | 0.005 |
| Loss of appetite | 5 (0.7) | 14 (2.9) | 0.003 | 4 (0.6) | 5 (1.0) | 0.372 |
| Allergy | 11 (1.6) | 14 (2.9) | 0.123 | 9 (1.3) | 11 (2.3) | 0.199 |
| Rash/Itching | 4 (0.6) | 11 (2.3) | 0.010 | 2 (0.3) | 7 (1.5) | 0.024 |
| Imbalance/Lethargic | 4 (0.6) | 5 (1.0) | 0.372 | 1 (0.1) | 1 (0.2) | 0.795 |
| High blood pressure | 5 (0.7) | 3 (0.6) | 0.841 | 2 (0.3) | 2 (0.4) | 0.713 |
| Low blood pressure | 6 (0.9) | 9 (1.9) | 0.132 | 2 (0.3) | 2 (0.4) | 0.713 |
| Anxiety | 17 (2.4) | 10 (2.1) | 0.673 | 6 (0.9) | 2 (0.4) | 0.356 |
| Uneasy feeling/tension | 36 (5.2) | 26 (5.4) | 0.876 | 0 (0.0) | 0 (0.0) | <0.001 |
Gender-based comparison of side effects between the 1st and 2nd doses of the COVID-19 vaccine.
Rash or itching showed a significant association after the first and second doses. Furthermore, in the case of allergy, imbalance, high blood pressure, low blood pressure, anxiety, or an uneasy feeling, there is no significant difference between males and females for either of the doses.
Table 3 presents the students’ information regarding the side effects of different types of vaccines. It is visible that both doses of the Moderna vaccine are significantly associated with the reporting of pain and edema and increased body temperature symptoms compared to the Covishield, Pfizer, Sinopharm, and Sinovac vaccines. More than half of the participants receiving the Moderna vaccine have reported pain, edema, and increased body temperature after the vaccination. Other vaccines, such as Covishield, Sinopharm, and Pfizer, showed mild side effects after vaccination.
Table 3
| Symptoms | After 1st dose of the COVID-19 vaccine frequency (%) | After 2nd dose of the COVID-19 vaccine frequency (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna | Covishield | Sinopharm | Pfizer | Sinovac | p-value | Moderna | Covishield | Sinopharm | Pfizer | Sinovac | p-value | |
| Pain and Edema | 48 (55.8) | 42 (40.0) | 114 (17.1) | 25 (36.8) | 4 (19.0) | <0.001 | 27 (31.4) | 10 (9.5) | 48 (7.2) | 2 (2.9) | 0 (0.0) | <0.001 |
| Headache | 30 (34.9) | 36 (34.3) | 73 (11.0) | 12 (17.6) | 1 (4.8) | <0.001 | 24 (27.9) | 13 (12.4) | 39 (5.9) | 5 (7.4) | 0 (0.0) | <0.001 |
| Increased body temperature | 53 (61.6) | 61 (58.1) | 80 (12.0) | 19 (27.9) | 4 (19.0) | <0.001 | 46 (53.5) | 16 (15.2) | 33 (5.0) | 6 (8.8) | 2 (9.5) | <0.001 |
| Loss of appetite | 3 (3.5) | 8 (7.6) | 4 (0.6) | 2 (2.9) | 0 (0.0) | <0.001 | 3 (3.5) | 2 (1.9) | 3 (0.5) | 1 (1.5) | 0 (0.0) | 0.062 |
| Allergy | 6 (7.0) | 2 (1.9) | 14 (2.1) | 2 (2.9) | 0 (0.0) | 0.059 | 5 (5.8) | 0 (0.0) | 14 (2.1) | 1 (1.5) | 0 (0.0) | 0.030 |
| Rash/Itching | 4 (4.7) | 2 (1.9) | 7 (1.1) | 1 (1.5) | 0 (0.0) | 0.190 | 1 (1.2) | 0 (0.0) | 6 (0.9) | 1 (1.5) | 0 (0.0) | 0.954 |
| Imbalance/Lethargic | 1 (1.2) | 3 (2.9) | 3 (0.5) | 1 (1.5) | 0 (0.0) | 0.329 | 1 (1.2) | 0 (0.0) | 0 (0.0) | 1 (1.5) | 0 (0.0) | 0.061 |
| High blood pressure | 1 (1.2) | 1 (1.0) | 4 (0.6) | 0 (0.0) | 1 (4.8) | 0.501 | 1 (1.2) | 1 (1.0) | 2 (0.3) | 0 (0.0) | 0 (0.0) | 0.780 |
| Low blood pressure | 2 (2.3) | 3 (2.9) | 8 (1.2) | 2 (2.9) | 0 (0.0) | 0.367 | 1 (1.2) | 1 (1.0) | 1 (0.2) | 1 (1.5) | 0 (0.0) | 0.428 |
| Anxiety | 4 (4.7) | 6 (5.7) | 13 (2.0) | 1 (1.5) | 0 (0.0) | 0.207 | 3 (3.5) | - | 5 (0.8) | - | - | 0.072 |
| Uneasy feeling/tension | 9 (10.5) | 9 (8.6) | 35 (5.3) | 2 (2.9) | 3 (14.3) | 0.018 | - | - | - | - | - | - |
Vaccine-wise side effects after each dose of the COVID-19 vaccine.
Table 4 represents the binary logistic predictors of COVID-19 vaccine side effects after the first dose. In the binary logistic regression model, the age group 22–24 has 1.335 times (aOR: 1.335, 95% CI: 1.012–1.763) higher odds of experiencing the side effect of COVID-19 vaccine than the age group 18–21. Female students are significantly 11.6% (aOR: 1.116, 95% CI: 0.846–1.472) more likely to experience any side effect of the COVID-19 vaccine than males. The table shows that students living in urban areas have 1.471 times (aOR: 1.471, 95% CI: 1.059–2.045) higher odds of experiencing side effects after the first dose than rural-based students.
Table 4
| Variable | aOR | B | p-value | 95% CI for EXP(B) | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Age (in years) | |||||
| 18-21(r) | |||||
| 22–24 | 1.335 | 0.289 | 0.041 | 1.012 | 1.763 |
| 25< | 1.247 | 0.220 | 0.382 | 0.760 | 2.044 |
| Sex | |||||
| Male(r) | |||||
| Female | 1.116 | 0.110 | 0.038 | 0.846 | 1.472 |
| Residence | |||||
| Rural(r) | |||||
| Sub-urban | 1.510 | 0.412 | 0.038 | 1.023 | 2.231 |
| Urban | 1.471 | 0.386 | 0.022 | 1.059 | 2.045 |
| Living status | |||||
| Alone(r) | |||||
| With family | 1.177 | 0.163 | 0.220 | 0.907 | 1.528 |
| Education | |||||
| Undergraduate(r) | |||||
| Postgraduates and others | 1.565 | 0.448 | 0.046 | 1.009 | 2.428 |
| COVID-19 Status | |||||
| Negative(r) | |||||
| Positive | 1.613 | 0.478 | 0.003 | 1.178 | 2.207 |
| Heath status | |||||
| Poor(r) | |||||
| Good | 0.810 | −0.210 | 0.299 | 0.545 | 1.205 |
| Excellent | 0.761 | −0.273 | 0.214 | 0.494 | 1.171 |
| Recovery | |||||
| Not applicable(r) | |||||
| 1–3 days | 4.615 | 1.529 | <0.001 | 2.642 | 8.060 |
| Above 3 days | 4.172 | 1.428 | 0.002 | 1.722 | 10.107 |
| Allergy | |||||
| No(r) | |||||
| Yes | 1.327 | 0.283 | 0.035 | 1.020 | 1.726 |
| Social Distance | |||||
| No(r) | |||||
| Yes | 0.669 | −0.402 | 0.006 | 0.501 | 0.893 |
| Covering mouth | |||||
| No(r) | |||||
| Yes | 1.557 | 0.443 | 0.003 | 1.158 | 2.094 |
Binary logistic estimates for side effects of the first dose of the vaccine.
r Indicates reference category; aOR Adjusted odds ratio.
Also, students living in suburban areas have 1.510 times (aOR: 1.510, 95% CI: 1.023–2.231) higher odds of experiencing side effects than rural respondents. Living arrangements have no impact on the side effects of the COVID-19 vaccine since they are statistically insignificant.
Table 4 also shows that postgraduate students are 1.565 times (aOR: 1.565, 95% CI: 1.009–2.428) more likely to experience the side effect of the COVID-19 vaccine than undergraduate students, with a p-value of 0.046. Health status and living arrangements have no impact on the side effects of the COVID-19 vaccine since the findings are not statistically significant.
Compared to students who did not contract SARS-CoV-2, those who did are 1.613 times (aOR: 1.613, CI: 1.178 to 2.207) more likely to experience any side effects following the initial dose. The recovery period is a significant factor; those students who needed 1–3 days to recover are 4.615 times (aOR: 4.615, 95% CI: 2.642–8.060) more likely to experience side effects after the first dose. Students who require more than 3 days to recover from COVID-19 are 4.172 times (aOR: 4.172, 95% CI: 1.722–10.107) more likely to experience side effects (p-value = 0.002). Allergy is a significant factor for side effects; respondents with allergies are 1.327 times (aOR: 1.327, 95% CI: 1.020–1.726) more likely to experience side effects after the first dose. Those who maintain a social distance of at least 15 meters in public spaces are 0.669 times (aOR: 0.669, 95% CI: 0.501–0.893) less likely, or 33.1% less likely, to experience any side effect of the COVID-19 vaccine after the first dose. Covering the mouth and nose when coughing and sneezing made people 1.557 times (aOR: 1.557, 95% CI: 1.158–2.094) more likely to experience side effects (p = 0.003).
5 Discussion
This study aimed to assess the perceptions and experiences of university students regarding the side effects of the COVID-19 vaccines in Bangladesh. The participants experienced different physical and mental illnesses after receiving the doses of the COVID-19 vaccine. This study shows that four out of five (84.4%) participants have taken at least one dose of any of the COVID-19 vaccines available for university students in Bangladesh. Some participants experienced pain and edema, growing body temperature, and headache after receiving the first dose, while very few reported uneasy feelings and tension after receiving the first dose. Likewise, after receiving the second dose, a few participants encountered body temperature, pain, edema, and headache. A similar result was found in a study in Bangladesh that observed a wide range of adverse side effects, such as fever, headache, and pain, where the vaccine was injected, which aligns with our study (23). Some other research revealed that the side effects caused by the COVID-19 vaccines are pain where the vaccine was injected, muscle pain, joint pain, fever, headache, tiredness, and fatigue (24–26), thus complementing the findings of our study. Usually a non-serious adverse event like pain, headache, and injection site pain are reported for every million doses administered (27). Injection site pain, headache, or fatigue was also common for 50% of participants in the clinical trial (28). The reported adverse effects after the first dose were non-serious and temporary in Bangladesh (9). From our study, it is also evident that the participant’s sex was substantially associated with the side effects of the COVID-19 vaccine after receiving both doses. Female participants were more likely to suffer from the general side effects than their male counterparts, which resembles previous studies (24, 29–33). Still, some contradictory results were found where no sex difference regarding the effects of the COVID-19 vaccine was reported among the vaccine recipients (34, 35). This may be due to information biases, as women are more likely to report their experiences than men (31). Besides, the difference between sex and endocrine hormones may play important roles in the higher report of side effects of the COVID-19 vaccine (36). Another reason may be that women are more susceptible to adverse events of pharmacokinetics and pharmacodynamics, or women may carry a significant percentage of body fat compared to men (37). The present study also suggested a significant relationship between different (symptoms) adverse effects and sex after receiving doses of the COVID-19 vaccine. For example, female students most likely suffered from pain, edema, and body temperature compared to male students. To the best of our knowledge, our study’s unique findings determined the association between sex and the specific type of adverse effects of COVID-19 vaccination.
This study uncovered another important aspect of COVID-19 vaccination, suggesting a significant association between vaccine types and side effects after vaccination (at least taking one of the doses). It was found that the majority of the participants received the Sinopharm vaccine, while others received Moderna, Covishield, and Pfizer-BioNTech vaccines. However it is seen that the first and second dose of the Moderna vaccine was significantly associated with higher reports of pain, edema, and body temperature symptoms compared to Covishield, Pfizer, Sinopharm, and Sinovac vaccines. More than half of the participants who received the Moderna vaccine reported feeling pain and body temperature after receiving it. This is similar to the findings of previous studies (32, 38–40). A possible reason for this outcome may be an inactive substance that serves as the vehicle or medium for other active agents utilized in the mRNA vaccine (Moderna). This agent serves as prevention against bacterial infections by invigorating a more grounded immune reaction, which may have significantly contributed to prompt reactions related to vaccination (41). Some of the other causes of these side effects may be due to a pre-existing physical problem (e.g., prior history of asthma, food or drug allergies), or it may be an unfortunate coincidence limited by medical science and has no relation with vaccination (42).
From binary logistic regression, some important predictors of side effects of the COVID-19 vaccine were identified. Female students were more likely to experience side effects of the COVID-19 vaccine than male students. Similar results were found in studies conducted in other countries, such as Saudi Arabia, Israel, the USA, Japan, and UAE (29–33, 36, 43). This study found that the participants with prior COVID-19 infection were more likely to experience side effects after taking the first dose. A cross-sectional study in the USA among healthcare workers with similar results acknowledged that the adverse reaction of the post-vaccination period was more prevalent among people who were infected by COVID-19 previously (42).
The age of the participants was another significant predictor of the possibility of experiencing adverse reactions after vaccination. Higher odds of side effects of the COVID-19 vaccine were found in the age group 22–24 compared to the age group 18–21, and this result is parallel with the findings of previous clinical trials in the Czech Republic, India, and Pakistan (37, 44, 45). The receptivity of the vaccine producing usual prospective adverse reactions declined with age as per these studies (37, 44, 45). However, it is not a possible cause of a desired resistant reaction (46).
We found inconsistent results demonstrating age as an independent predictor of the vaccine’s side effects (47). Another study claimed that they could not imbed a relationship between the vaccine’s adverse effects and age (48). A significant relationship was observed between the students having allergies and the side effects of the COVID-19 vaccine after the first dose. The participants with allergies were more likely to experience adverse effects after taking the first dose of the COVID-19 vaccine than those with no history of allergy. Some previous studies support this finding that the allergic history of the participants is usually the associated reason for adverse reactions to the COVID-19 vaccine (29, 38, 49, 50).
6 Strength and limitation
To the best of the authors’ knowledge, this is the first study to investigate the side effects of several COVID-19 vaccines among university students in Bangladesh. Previous studies on this particular topic focused mostly on healthcare workers and general people. Since university students are educated and adults, their responses recorded are mostly reliable. However, the study has several limitations too. Due to the convenience sampling approach, there might be some selection biases. Second, since the study was online, voluntary, and self-administered, we cannot confirm the seriousness of all participants while filling out the e-questionnaire, causing potential information bias. Third, the study participants are limited to university students aged 18–30, which may restrict generalization of the findings for other age groups. Fourth, the survey is online based so a group of students might miss the opportunity to be included in the survey due to lack of online facilities. Fifth, we do not have any information after the third, fourth or other consecutive doses of the vaccines, which might reflect a different scenario. Future studies should try to address these issues with more inclusive analysis and data collection strategies.
7 Conclusion
The COVID-19 vaccination effectively protects against fatal disease, hospitalization, and death. However, the recipients reported a wide range of side effects, which may not be severe or fatal. It is reported that side effects (pain and edema, body temperature, and headache) were reported mainly by recipients of Moderna, while recipients of other vaccines (Covishield, Sinopharm, and Pfizer) also showed side effects after vaccination, though they were mild (allergies, anxiety, and uneasy feelings). Side effects were mainly reported after the first dose of the COVID-19 vaccination. Side effects of the COVID-19 vaccine varied between sexes, previous infection status, and individuals with allergy issues. Finally, this study’s findings might help policymakers choose the vaccine for the mass population with minimal side effects.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/NIIRDQ.
Ethics statement
The studies involving humans were approved by Khulna University Ethical Clearance Committee (Protocol Number – KUECC-2021/11/32). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their online informed consent to participate in this study. Online informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Moreover, the participants were free to decline the online survey without providing any prior explanation.
Author contributions
MAI: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Supervision, Writing – original draft, Writing – review & editing. MTN: Data curation, Formal analysis, Methodology, Software, Writing – original draft. AR: Investigation, Writing – original draft, Writing – review & editing. ASMMAH: Data curation, Investigation, Writing – original draft. UJJ: Data curation, Investigation, Writing – original draft. TT: Data curation, Investigation, Writing – original draft. SDB: Data curation, Investigation, Methodology, Writing – original draft. ST: Data curation, Investigation, Writing – original draft. AAM: Data curation, Investigation, Writing – original draft. SP: Data curation, Investigation, Writing – original draft. JN: Data curation, Investigation, Writing – original draft. RaWA: Writing – review & editing, Funding acquisition, Resources. ReWA: Resources, Writing – review & editing. MTH: Conceptualization, Validation, Writing – review & editing, Supervision.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
This work was supported by Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2024R 343), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
RichiFTAlamSAhmedFAl-hossainASMM (2022) The outbreak of Delta Plus variant: The notorious and novel strain of SARS-CoV-2. Clin Epidemiol Glob Heal100974. doi: 10.1016/j.cegh.2022.100974
2.
AlamSSarkerMMRAfrinSRichiFTZhaoCZhouJRet al. (2021a). Traditional herbal medicines, bioactive metabolites, and plant products against COVID-19: update on clinical trials and mechanism of actions. Frontiers in pharmacology, 12, 671498. doi: 10.3389/fphar.2021.671498
3.
ChowdhuryMNRAlifYAAlamSEmonNURichiFTZihadSNKet al. (2022). Theoretical effectiveness of steam inhalation against SARS-CoV-2 infection: updates on clinical trials, mechanism of actions, and traditional approaches. Heliyon, 8. doi: 10.1016/j.heliyon.2022.e08816
4.
World Health Organization (2023) data.who.int, WHO Coronavirus (COVID-19) dashboard > Vaccines [Dashboard]. Retrived on 17th March, 2024. Retrieved from:https://data.who.int/dashboards/covid19/vaccines
5.
HridoyAEEENaimMAlamEEmonNNUTipoIHTusherSMSHet al. (2020). Estimation of Effective Reproduction Number for COVID-19 in Bangladesh and its districts. medRxiv, 2020–08. doi: 10.1101/2020.08.04.20168351
6.
BanikRRahmanMSikderTGozalD (2020). COVID-19 in Bangladesh: public awareness and insufficient health facilities remain key challenges. Public health, 183, 50. doi: 10.1016/j.puhe.2020.04.037
7.
AlamSKamalTBSarkerMMRZhouJRRahmanSAMohamedI. N. (2021b). Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing. in Frontiers in Pharmacology, 12, 659577. doi: 10.3389/fphar.2021.659577
8.
PolandGAOvsyannikovaIGKennedyRBHaralambievaIHJacobsonRM (2011). Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics: a journal of integrative biology, 15, 625–636. doi: 10.1089/omi.2011.0032
9.
IslamMRHasanMNasreenWTusharMIBhuiyanMA (2021a). The covid-19 vaccination experience in bangladesh: Findings from a cross-sectional study. International Journal of Immunopathology and Pharmacology, 35, 20587384211065628. doi: 10.1177/20587384211065628
10.
HossainMEIslamMSGhoseTKJahanHChakroborttySHossenMSet al. (2021). COVID-19 vaccine acceptability among public university students in Bangladesh: Highlighting knowledge, perceptions, and attitude. Human vaccines & immunotherapeutics, 17, 5089–5098. doi: 10.1080/21645515.2021.2010426
11.
AbedinMIslamMARahmanFNRezaHMHossainMZHossainMAet al. Willingness to vaccinate against covid-19 among bangladeshi adults: understanding the strategies to optimize vaccination coverage. PLoS One. (2021) 16:e0250495. doi: 10.1371/journal.pone.0250495
12.
SallamM. (2021). vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines, 9, 160. doi: 10.3390/vaccines9020160
13.
DeRooSSPudalovNJFuLY (2020). Planning for a COVID-19 vaccination program. Jama, 323, 2458–2459. doi: 10.1001/jama.2020.8711
14.
JarrettCWilsonRO’LearyMEckersbergerELarsonHJ (2015). Strategies for addressing vaccine hesitancy–A systematic review. Vaccine, 33, 4180–4190. doi: 10.1016/j.vaccine.2015.04.040
15.
MacDonaldNE. Vaccine hesitancy: definition, scope and determinants. Vaccine. (2015) 33:4161–4. doi: 10.1016/j.vaccine.2015.04.036
16.
MacDonaldNE. (2015). Vaccine hesitancy: Definition, scope and determinants. Vaccine, 33, 4161–4164.
17.
PaulASikdarDMahantaJGhoshSJabedMAPaulSet al. (2021). Peoples’ understanding, acceptance, and perceived challenges of vaccination against COVID-19: A cross-sectional study in Bangladesh. PloS one, 16, e0256493. doi: 10.1371/journal.pone.0256493
18.
AliMHossainA. (2021). What is the extent of COVID-19 vaccine hesitancy in Bangladesh? A cross-sectional rapid national survey. BMJ open, 11, e050303. doi: 10.1136/bmjopen-2021-050303
19.
IslamMSSiddiqueABAkterRTasnimRSujanMSHWardPRet al. (2021b). Knowledge, attitudes and perceptions towards COVID-19 vaccinations: a cross-sectional community survey in Bangladesh. BMC public health, 21, 1–11. doi: 10.1186/s12889-021-11880-9
20.
KalamMADavis JrTPShanoSUddinMNIslamMAKanwagiRet al. (2021). Exploring the behavioral determinants of COVID-19 vaccine acceptance among an urban population in Bangladesh: Implications for behavior change interventions. PloS one, 16, e0256496. doi: 10.1371/journal.pone.0256496
21.
ElaMZShohelTAShovoS-TEKhanLJahanNHossainMTet al. (2021). Prolonged lockdown and academic uncertainties in bangladesh: A qualitative investigation during the covid-19 pandemic. Heliyon, 7, e06263. doi: 10.1016/j.heliyon.2021.e06263
22.
ElgendyMOEl-GendyAOMahmoudSMohammedTYAbdelrahimMESayedAMet al. (2022). Side effects and efficacy of COVID-19 vaccines among the Egyptian population. Vaccines, 10, 109. doi: 10.3390/vaccines10010109
23.
IslamMRHasanMNasreenWTusharMIBhuiyanMA. The COVID-19 vaccination experience in Bangladesh: findings from a cross-sectional study. Int J Immunopathol Pharmacol. (2021) 35:205873842110656.
24.
El-ShitanyNAHarakehSBadr-EldinSMBagherAMEidBAlmukadiHet al. Minor to moderate side effects of pfizer-biontech covid-19 vaccine among saudi residents: A retrospective cross-sectional study. Int J Gen Med. (2021):1389–401.
25.
RiadAPokornáAAttiaSKlugarováJKoščíkMKlugarM. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. (2021) 10:1428. doi: 10.3390/jcm10071428
26.
ZewudeBHabtegiorgisTHizkealADelaTSirawG. Perceptions and experiences of COVID-19 vaccine side-effects among healthcare workers in southern Ethiopia: a cross-sectional study. Pragmatic Observ. Res. (2021) 12:131–45. doi: 10.2147/POR.S344848
27.
CDC (n.d.) COVID-19 vaccine safety updatehttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf
28.
MA COVID-19 Vaccine AstraZeneca (2021) Retrived from:https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf (Accessed 26th March, 2024).
29.
CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of moderna covid-19 vaccine - United States, december 21, 2020-january 10, 2021. MMWR Morb Mortal Wkly Rep. (2021) 70:125–9. doi: 10.15585/mmwr.mm7004e1
30.
GeeJMarquezPSuJCalvertGMLiuRMyersTet al. First month of covid-19 vaccine safety monitoring—United States, december 14, 2020–january 13, 2021. Morb Mortal Wkly Rep. (2021) 70:283–8. doi: 10.15585/mmwr.mm7008e3
31.
GreenMSPeerVMagidAHaganiNAnisENitzanD. Gender differences in adverse events following the pfizer-biontech covid-19 vaccine. Vaccine. (2022) 10:233. doi: 10.3390/vaccines10020233
32.
HeidariSPalmer-RossAGoodmanT. A systematic review of the sex and gender reporting in covid-19 clinical trials. Vaccine. (2021) 9:1322. doi: 10.3390/vaccines9111322
33.
SomiyaMMineSYasukawaKIkedaS. Sex differences in the incidence of anaphylaxis to lnp-mrna covid-19 vaccines. Vaccine. (2021) 39:3313–4. doi: 10.1016/j.vaccine.2021.04.066
34.
KangYMLimJChoeK-WLeeK-DJoDHKimMJet al. Reactogenicity after the first and second doses of bnt162b2 mrna coronavirus disease vaccine: A single-center study. Clin Exp Vaccine Res. (2021) 10:282–9. doi: 10.7774/cevr.2021.10.3.282
35.
XiongXYuanJLiMJiangBLuZK. Age and gender disparities in adverse events following covid-19 vaccination: real-world evidence based on big data for risk management. Front Med. (2021) 8:700014. doi: 10.3389/fmed.2021.700014
36.
SchwartzJB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. (2003) 42:107–21. doi: 10.2165/00003088-200342020-00001
37.
ZuckerIPrendergastBJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. (2020) 11:1–14. doi: 10.1186/s13293-020-00308-5
38.
McMahonDEAmersonERosenbachMLipoffJBMoustafaDTyagiAet al. Cutaneous reactions reported after moderna and pfizer covid-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. (2021) 85:46–55. doi: 10.1016/j.jaad.2021.03.092
39.
MeoSBukhariIAkramJMeoAKlonoffDC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of pfizer/biontech and moderna vaccines. Eur Rev Med Pharmacol Sci. (2021) 25:1663–1669.
40.
WadmanM. Public needs to prep for vaccine side effects. Science. (2020) 370:1022. doi: 10.1126/science.370.6520.1022
41.
TrougakosIPTerposEAlexopoulosHPolitouMParaskevisDScorilasAet al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in molecular medicine. (2022) 28:542–554. doi: 10.1016/j.molmed.2022.04.007
42.
KadaliRAKJanagamaRYedlapatiSHKanikeNGajulaVMadathalaRRet al. Side effects of messenger rna vaccines and prior history of covid-19, a cross-sectional study. Am J Infect Control. (2022) 50:8–14. doi: 10.1016/j.ajic.2021.10.017
43.
SaeedBQAl-ShahrabiRAlhajSSAlkokhardiZMAdreesAO. Side effects and perceptions following sinopharm COVID-19 vaccination. Int J Infect Dis. (2021) 111:219–26. doi: 10.1016/j.ijid.2021.08.013
44.
JayadevanRShenoyRAnithadeviTS. Survey of symptoms following COVID-19 vaccination in India. medRxiv. (2021)
45.
PolackFPThomasSJKitchinNAbsalonJGurtmanALockhartSet al. Safety and efficacy of the bnt162b2 mrna covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577
46.
HervéCLaupèzeBDel GiudiceGDidierlaurentAMTavares Da SilvaF. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. (2019) 4:1–11. doi: 10.1038/s41541-019-0132-6
47.
CogginsS. A. A.LaingE. D.OlsenC. H.GoguetE.MoserM.Jackson-ThompsonB. M.et al. (2022). Adverse effects and antibody titers in response to the bnt 162b2 mrna COVID-19 vaccine in a prospective study of healthcare workers. Paper presented at the Open forum infectious diseases, 9
48.
Andrzejczak-GrządkoSCzudyZDonderskaM. Side effects after covid-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. (2021) 25:4418–21. doi: 10.26355/eurrev_202106_26153
49.
AhamadM. M.AktarS.UddinM. J.Rashed-Al-MahfuzM.AzadA.UddinS.et al. (2022). Adverse effects of covid-19 vaccination: machine learning and statistical approach to identify and classify incidences of morbidity and postvaccination reactogenicity. Paper presented at the Healthcare, 11
50.
GarveyLHNasserS. Anaphylaxis to the first covid-19 vaccine: is polyethylene glycol (peg) the culprit?Br J Anaesth. (2021) 126:e106–8. doi: 10.1016/j.bja.2020.12.020
Summary
Keywords
COVID-19, vaccine, experience, side effects, university students, Bangladesh
Citation
Islam MA, Nahar MT, Rahman A, Monjur Al Hossain ASM, Jui UJ, Tabassum T, Barna SD, Tahmida S, Mishu AA, Parvin S, Naime J, Attar RW, Attar RW and Hossain MT (2024) Experience and side effects of COVID-19 vaccine uptake among university students: a cross-sectional survey study. Front. Public Health 12:1361374. doi: 10.3389/fpubh.2024.1361374
Received
25 December 2023
Accepted
22 April 2024
Published
24 June 2024
Volume
12 - 2024
Edited by
Rizwan Ahmed Laar, Hubei Normal University, China
Reviewed by
Huilin Wang, Hunan University of Science and Technology, China
Rashid Menhas, Zhejiang University, China
Updates
Copyright
© 2024 Islam, Nahar, Rahman, Monjur Al Hossain, Jui, Tabassum, Barna, Tahmida, Mishu, Parvin, Naime, Attar, Attar and Hossain.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Md. Tanvir Hossain, tanvirku05@soc.ku.ac.bd
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.